Nuvation Bio (NUVB) EBITDA (2023 - 2025)

Historic EBITDA for Nuvation Bio (NUVB) over the last 3 years, with Q3 2025 value amounting to -$55.6 million.

  • Nuvation Bio's EBITDA fell 4419.0% to -$55.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$219.0 million, marking a year-over-year increase of 5849.16%. This contributed to the annual value of -$567.5 million for FY2024, which is 70968.26% down from last year.
  • Per Nuvation Bio's latest filing, its EBITDA stood at -$55.6 million for Q3 2025, which was down 4419.0% from -$59.9 million recorded in Q2 2025.
  • In the past 5 years, Nuvation Bio's EBITDA registered a high of -$10.3 million during Q4 2023, and its lowest value of -$462.6 million during Q2 2024.
  • Moreover, its 3-year median value for EBITDA was -$38.6 million (2024), whereas its average is -$74.0 million.
  • Per our database at Business Quant, Nuvation Bio's EBITDA crashed by 199344.71% in 2024 and then soared by 8705.59% in 2025.
  • Over the past 3 years, Nuvation Bio's EBITDA (Quarter) stood at -$10.3 million in 2023, then tumbled by 387.51% to -$50.3 million in 2024, then dropped by 10.65% to -$55.6 million in 2025.
  • Its last three reported values are -$55.6 million in Q3 2025, -$59.9 million for Q2 2025, and -$53.3 million during Q1 2025.